We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Sorted Muscle Progenitor Cells Reverse Muscular Dystrophy in a Mouse Model

By Biotechdaily staff writers
Posted on 07 Feb 2008
A recent report described the isolation of specific muscle tissue progenitor cells from a general population of embryonic stem cells and their potential use as a treatment for muscular dystrophy.

Investigators from the University of Texas Southwestern Medical Center (Dallas, USA) worked with a mouse model of human Duchenne muscular dystrophy that lacked the gene for the protein dystrophin.

Dystrophin is a rod-shaped cytoplasmic protein, and a vital part of a protein complex that connects the cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the cell membrane. More...
Dystrophin has the longest gene known to date, measuring 2.5 megabases (0.1% of the human genome). Its gene's locus is Xp21 and has 97 exons, produces an mRNA of 14.6 kilobases and a protein of over 3500 amino acid residues.
To stimulate dystrophin production in embryonic stem cells, the investigators activated the Pax3 gene, which functions in muscle progenitor cells. However, when these cells were injected into mouse muscle, they caused the formation of teratomas, tumors containing cells of many different types of tissue.

To avoid tumor formation, the investigators utilized a fluorescent cell sorting process to concentrate muscle progenitor cells while rejecting undifferentiated, tumorogenic cells. Results published in the January 20, 2008, online edition of the journal Nature Medicine revealed that after the sorted cells were injected into the mice, they deeply penetrated the muscle tissue forming new muscle fiber. Many of the new muscle fiber cells contained dystrophin. Furthermore, after three months, the mice showed no signs of tumors.

"The problem had been that embryonic stem cells make everything,” explained senior author Dr. Rita Perlingeiro, assistant professor of developmental and molecular biology at the University of Texas Southwestern Medical Center. "They make a great variety of cells. The trick is to pull out only the one type you want. Even if there are 10 undesirable cells, that is too many. We envision eventually developing a stem-cell therapy for humans with muscular dystrophy, if we are able to successfully combine this approach with the technology now available to make human embryonic stem cells from reprogrammed skin cells. These cells can be transplanted into the muscle, and they cause muscle regeneration resulting in stronger contractility.”


Related Links:
University of Texas Southwestern Medical Center

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.